Who is sponsoring NCT03308149?

NCT03308149 is sponsored by University Hospital Tuebingen.

What drugs are being tested in NCT03308149?

Interventions in NCT03308149: infiltration with triamcinolone and bupivacaine.

What condition does NCT03308149 study?

NCT03308149 studies Infiltration Facet Joint.

Is NCT03308149 still recruiting?

NCT03308149 is currently completed. Last updated 12 October 2017.

Last reviewed 2017-10-12 · How we verify

NCT03308149

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Predictability of the Effects of Facet Joint Infiltration in the Degenerate Lumbar Spine When Assessing MRI Scans

Completed Last updated 12 October 2017

What this trial tests

trial testing infiltration with triamcinolone and bupivacaine in Infiltration Facet Joint in 50 participants. Completed in 10 January 2017.

Timeline

10 January 2016

Primary endpoint
10 January 2017

10 January 2017

Quick facts

Lead sponsor	University Hospital Tuebingen
Status	Completed
Study type	OBSERVATIONAL
Enrollment	50
Start date	10 January 2016
Primary completion	10 January 2017
Estimated completion	10 January 2017
Sites	1 location across Germany

Drugs / interventions tested

infiltration with triamcinolone and bupivacaine — full drug profile →

Conditions studied

Infiltration Facet Joint — all drugs for Infiltration Facet Joint →

Sponsor

University Hospital Tuebingen

Who can join

Eligibility, any sex, with Infiltration Facet Joint. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Fifty MRI scans of patients with chronic lumbar back pain were graded radiologically using a wide range of classification and measurement systems. The reported effect of facet joint injections at the site was recorded and a comparative analysis performed.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Predictability of the effects of facet joint infiltration in the degenerate lumbar spine when assessing MRI scans.
Hofmann UK, Keller RL, Walter C, Mittag F. · · 2017 · cited 13× · PMID 29162138 · DOI 10.1186/s13018-017-0685-x

Verify or expand the search:

Other University Hospital Tuebingen trials

Trials by the same sponsor.

NCT07378670 — DEfeating PEnile CAncer-2 · NA · recruiting
NCT07276503 — Verification of a New Predictive Delirium Score in Adults With Elective Cardiac Valve or Bypass Surgery With Perioperati · not yet recruiting
NCT07411365 — Dual-task Cognitive-motor Telerehabilitation in Persons With PD-MCI · NA · not yet recruiting
NCT06953791 — Comparison of Quality of Life During a Flare of Crohn's Disease Treated With Prednisolone or aCDED With PEN in Adult Pat · Phase 2 · recruiting
NCT07378891 — Artificial-Intelligence-based Early Detection of Diabetic Retinopathy (FUNDUS AI) · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03308149 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital Tuebingen
Last refreshed: 12 October 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03308149.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing